Y-mAbs Therapeutics, Inc. has presented preclinical and translational pharmacokinetic data of their GD2-SADA bispecific fusion protein at the 2025 Society of Nuclear Medicine & Molecular Imaging ...
Y-mAbs announces GD2-SADA clinical trial presentation for treating GD2-expressing tumors at the Advances in Neuroblastoma Research Meeting. Y-mAbs Therapeutics, Inc. has announced the presentation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback